^
Association details:
| Biomarker: | ALK positive |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Excerpt:
...antitumour activity of crizotinib in children with refractory solid tumours and anaplastic large-cell lymphoma. Objective tumour responses were documented in 14 of 79 patients (nine complete responses, five partial responses); and the anti-tumour activity was enriched in patients with known activating ALK aberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblastoma, three of seven with inflammatory myofibroblastic tumour, and one of two with NSCLC).
DOI:
10.1016/S1470-2045(13)70095-0
Trial ID:
